# COVID Supplement

> **NIH NIH N01** · UNIVERSITY OF CHICAGO · 2020 · $319,510

## Abstract

The contractor had previously discovered inhibitors of the NFkB-pathway which inhibited systemic inflammation when delivered together with a TLR-agonist, while improving antibody responses induced by vaccines formulated with this combination adjuvant. They will apply this finding to subunit SARS-CoV2 vaccines and test the immunogenicity and efficacy of such novel vaccine formulations.

## Key facts

- **NIH application ID:** 10285328
- **Project number:** 75N93019C00041-P00001-9999-2
- **Recipient organization:** UNIVERSITY OF CHICAGO
- **Principal Investigator:** AARON ESSER-KAHN
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $319,510
- **Award type:** —
- **Project period:** 2019-09-30 → 2021-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10285328

## Citation

> US National Institutes of Health, RePORTER application 10285328, COVID Supplement (75N93019C00041-P00001-9999-2). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10285328. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*